Pharvaris(NASDAQ) PHVS

Pharvaris N.V. is a late-stage biopharmaceutical company dedicated to developing therapies for rare diseases, particularly those related to angioedema. The company is advancing its lead product, deucrictibant, a small molecule bradykinin B2-receptor antagonist, through phase 3 clinical trials for treating hereditary and acquired angioedema.

Products and Services

• Deucrictibant for treating bradykinin-mediated angioedema
• Extended-release and immediate-release formulations of deucrictibant
• Focus on therapies for rare diseases with unmet medical needs

Growth Outlook

• Phase 3 trials for deucrictibant are progressing, indicating potential market entry
• Strong pipeline targeting rare diseases may attract strategic partnerships
• Market demand for effective angioedema treatments is increasing

Financial Highlights

• Cash and cash equivalents of €246.96 million as of March 31, 2026
• Operating expenses of €44.89 million in Q1 2026, reflecting ongoing R&D investments
• Net income of -€39.85 million in Q1 2026, consistent with development phase

Pharvaris N.V. is positioned in the biotechnology sector, focusing on innovative treatments for rare diseases. The company's lead product, deucrictibant, is currently in phase 3 trials, which is a critical stage for potential commercialization. The financial data indicates a robust cash position, allowing for continued investment in research and development. Despite reporting a net loss, the ongoing clinical trials and the potential for market entry highlight the company's commitment to addressing significant unmet medical needs in the angioedema space. The increasing demand for effective treatments in this area further supports the company's growth potential.